During the recent session, Legend Biotech Corp ADR (NASDAQ:LEGN)’s traded shares were 0.43 million, with the beta value of the company hitting 0.18. At the last check today, the stock’s price was $36.02, reflecting an intraday loss of -3.79% or -$1.42. The 52-week high for the LEGN share is $70.13, that puts it down -94.7 from that peak though still a striking 16.24% gain since the share price plummeted to a 52-week low of $30.17. The company’s market capitalization is $6.61B, and the average intraday trading volume over the past 10 days was 1.78 million shares, and the average trade volume was 1.49 million shares over the past three months.
Legend Biotech Corp ADR (LEGN) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.22. LEGN has a Sell rating from 0 analyst(s) out of 11 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 11 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.38.
Legend Biotech Corp ADR (NASDAQ:LEGN) trade information
Legend Biotech Corp ADR (LEGN) registered a -3.79% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -3.79% in intraday trading to $36.02, hitting a weekly high. The stock’s 5-day price performance is 14.25%, and it has moved by 5.89% in 30 days. Based on these gigs, the overall price performance for the year is -35.90%. The short interest in Legend Biotech Corp ADR (NASDAQ:LEGN) is 20.9 million shares and it means that shorts have 15.58 day(s) to cover.
The consensus price target of analysts on Wall Street is $91, which implies an increase of 60.42% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $83 and $94 respectively. As a result, LEGN is trading at a discount of -160.97% off the target high and -130.43% off the low.
Legend Biotech Corp ADR (LEGN) estimates and forecasts
Statistics show that Legend Biotech Corp ADR has underperformed its competitors in share price, compared to the industry in which it operates. Legend Biotech Corp ADR (LEGN) shares have gone down -39.84% during the last six months, with a year-to-date growth rate less than the industry average at 15.65% against 16.50. In the rating firms’ projections, revenue will increase 116.13% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 178.89M as predicted by 14 analyst(s). Meanwhile, a consensus of 7 analyst(s) estimates revenue growth to 195.69M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 79.46M and 93.99M respectively. In this case, analysts expect current quarter sales to grow by 125.12% and then jump by 108.20% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -168.48%. While earnings are projected to return 41.49% in 2025.
LEGN Dividends
Legend Biotech Corp ADR is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Legend Biotech Corp ADR (NASDAQ:LEGN)’s Major holders
The next largest institutional holding, with 11.49 million shares, is of PRICE T ROWE ASSOCIATES INC /MD/’s that is approximately 6.3126% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $508.86 million.
Also, the Mutual Funds coming in first place with the largest holdings of Legend Biotech Corp ADR (LEGN) shares are Fidelity Select Portfolios – Health Care and Price (T.Rowe) Growth Stock Fund Inc. Data provided on Nov 30, 2024 indicates that Fidelity Select Portfolios – Health Care owns about 2.62 shares. This amounts to just over 1.43 percent of the company’s overall shares, with a $95.17 million market value. The same data shows that the other fund manager holds slightly less at 2.32, or about 1.27% of the stock, which is worth about $84.35 million.
